Condition: Metastatic Triple-Negative Breast Carcinoma · Breast Cancer · Sponsor: Baylor Research Institute
The goal of this clinical trial is to assess the safety and efficacy of combined ruxolitinib and neratinib in patients with chemotherapy-pretreated metastatic triple negative breast cancer. This trial will evaluate one dosing schedule of neratinib in ruxolitinib in patients with metTNBC with locoregional recurrence.
This description comes directly from the study's public registry record.
Page E Blas, MA · 214-820-5424 · page.blas@bswhealth.org
Always discuss trial participation with your own doctor first.
| Baylor University Medical Center, Baylor Charles A Sammons Cancer Center | Dallas, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06008275